These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34630114)

  • 1. Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth.
    Cruz Flores VA; Menghani H; Mukherjee PK; Marrero L; Obenaus A; Dang Q; Khoutorova L; Reid MM; Belayev L; Bazan NG
    Front Pharmacol; 2021; 12():746470. PubMed ID: 34630114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration.
    Bazan NG; Reid MM; Flores VAC; Gallo JE; Lewis W; Belayev L
    Cancer Metastasis Rev; 2021 Sep; 40(3):643-647. PubMed ID: 34519960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking pro-inflammatory platelet-activating factor receptors and activating cell survival pathways: A novel therapeutic strategy in experimental ischemic stroke.
    Belayev L; Obenaus A; Mukherjee PK; Knott EJ; Khoutorova L; Reid MM; Roque CR; Nguyen L; Lee JB; Petasis NA; Oria RB; Bazan NG
    Brain Circ; 2020; 6(4):260-268. PubMed ID: 33506149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior Neuroprotective Efficacy of LAU-0901, a Novel Platelet-Activating Factor Antagonist, in Experimental Stroke.
    Belayev L; Eady TN; Khoutorova L; Atkins KD; Obenaus A; Cordoba M; Vaquero JJ; Alvarez-Builla J; Bazan NG
    Transl Stroke Res; 2012 Mar; 3(1):154-63. PubMed ID: 22408693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-Activating Factor (PAF) Receptor Antagonism Modulates Inflammatory Signaling in Experimental Uveitis.
    Elison JR; Weinstein JE; Sheets KG; Regan CE; Lentz JJ; Reinoso M; Gordon WC; Bazan NG
    Curr Eye Res; 2018 Jun; 43(6):821-827. PubMed ID: 29641916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
    Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
    J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma.
    Hicks MJ; Funato K; Wang L; Aronowitz E; Dyke JP; Ballon DJ; Havlicek DF; Frenk EZ; De BP; Chiuchiolo MJ; Sondhi D; Hackett NR; Kaminsky SM; Tabar V; Crystal RG
    Cancer Gene Ther; 2015 Jan; 22(1):1-8. PubMed ID: 25501993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avastin® in combination with gemcitabine and cisplatin significantly inhibits tumor angiogenesis and increases the survival rate of human A549 tumor-bearing mice.
    Liu Y; Xia X; Zhou M; Liu X
    Exp Ther Med; 2015 Jun; 9(6):2180-2184. PubMed ID: 26136956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
    Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
    Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme.
    Qin Y; Takahashi M; Sheets K; Soto H; Tsui J; Pelargos P; Antonios JP; Kasahara N; Yang I; Prins RM; Braun J; Gordon LK; Wadehra M
    J Neurooncol; 2017 Aug; 134(1):29-40. PubMed ID: 28597184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
    de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
    Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approaches to combat chemoresistance against glioblastomas.
    Towner RA; Zalles M; Saunders D; Smith N
    Cancer Drug Resist; 2020; 3(4):686-698. PubMed ID: 35582224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
    Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
    Hall WA; Vallera DA
    Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect.
    Szentirmai O; Baker CH; Lin N; Szucs S; Takahashi M; Kiryu S; Kung AL; Mulligan RC; Carter BS
    Neurosurgery; 2006 Feb; 58(2):365-72; discussion 365-72. PubMed ID: 16462491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.